Body Pharm AOD 9604 2

Body Pharm AOD-9604 2mg is a research-grade lyophilised peptide corresponding to the lipolytic C-terminal fragment of human growth hormone (residues 176–191, molecular weight ≈1.81 kDa), supplied in South Africa through JCSG.org for in vitro fat-metabolism work.

Key Takeaways

• AOD-9604 is a 16-amino-acid HGH fragment that stimulates fat breakdown without raising IGF-1 levels
• Batch-specific Certificate of Analysis (≥99% purity by HPLC) is essential before use
• AOD-9604 is unregistered with SAHPRA and prohibited under WADA 2025 for human or athletic use
• Current ZAR pricing and lot traceability from JCSG.org are the primary procurement inputs
• Reconstitution requires bacteriostatic water and careful handling to preserve the disulfide bridge

For researchers looking to buy AOD-9604 peptide in South Africa, the procurement decision rests on three verifiable inputs:

• A batch-specific Certificate of Analysis confirming ≥99% purity (this confirms the peptide meets specification before use)
• Current ZAR pricing from the live JCSG.org listing
• Awareness that AOD-9604 remains unregistered with SAHPRA and is prohibited under the WADA 2025 list for human performance use (meaning it cannot be used in athletes or for therapeutic claims)

The sections below cover the HGH fragment 176–191 mechanism, the South African regulatory position, Body Pharm's 2mg vial specifications, and a side-by-side comparison against CJC-1295, ipamorelin, and tesamorelin available from local suppliers.

What Is AOD-9604? The HGH Fragment Explained

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to residues 176–191 of the C-terminus of human growth hormone, with an added N-terminal tyrosine and a calculated molecular weight of approximately 1.81 kDa (≈1,817 Da). It was engineered to isolate the lipolytic domain of HGH while excluding the growth-promoting and IGF-1-stimulating regions of the parent hormone, so it acts on fat cells without triggering systemic growth signals. The synonym "HGH fragment 176–191" refers to the same molecule.

Origin and structural rationale

Heffernan and colleagues (2001) characterised the C-terminal fragment in obese Zucker rats and showed that its lipolytic and anti-lipogenic activity was retained independently of the receptor-binding regions that drive somatogenic effects. Earlier adipocyte work by Ng and co-workers (2000) had already mapped the fragment's action to β3-adrenergic pathway modulation in fat cells. Metabolic Pharmaceuticals later used this mechanistic basis to carry the compound into human trials.

The sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Gly-Phe-Tyr-Leu-Leu carries an intramolecular disulfide bridge that stabilises the active conformation. For researchers building a procurement file, this structural identity links the AOD-9604 category page listings back to the original Metabolic Pharmaceuticals patent chemistry, and is the basis on which AOD-9604 is differentiated from longer-acting GH secretagogues such as tesamorelin.

Mechanism: How AOD-9604 Signals Fat Metabolism

AOD-9604 acts on adipocytes through two coupled effects: stimulation of lipolysis (hydrolysis of stored triglycerides into free fatty acids and glycerol) and suppression of lipogenesis (inhibition of new triglyceride synthesis). Published preclinical models show no measurable elevation of IGF-1 or insulin. That decoupling from the somatogenic arm of GH is what makes the fragment useful as a chemical probe for fat-cell energy balance rather than as a growth-axis agonist.

The β3-adrenergic hypothesis

Ng and colleagues (2000) attributed the lipolytic signal in cultured adipocytes to modulation of the β3-adrenergic receptor pathway, with downstream activation of hormone-sensitive lipase as the proposed effector step. Heffernan et al. (2001), working in obese Zucker rats, showed that the same C-terminal sequence reduced lipogenic enzyme expression while increasing fat oxidation, and that ablation of β3 signalling attenuated the response. Receptor-level confirmation in human adipose tissue remains incomplete. For in vitro protocols, I treat the β3 link as the working hypothesis rather than as a settled mechanism.

What the human data actually covers

Clinical evidence is anchored to the Metabolic Pharmaceuticals Phase IIb obesity programme (circa 2004), which reported modest weight-loss effects and a clean IGF-1/insulin profile at the doses tested. No Phase III replication followed, and the compound was effectively withdrawn from therapeutic development. PubMed and ClinicalTrials.gov searches through 2025 return no large-scale human randomised controlled trials that update those endpoints.

Researchers building a 2026 protocol should cite the Phase IIb dataset with explicit age-of-evidence caveats and design assays that generate fresh primary data rather than extrapolating from two-decade-old results.

For comparative GH-axis context, the AOD-9604 category page and the tesamorelin research peptide listing show how a non-secretagogue fragment differs mechanistically from a GHRH analogue that does raise IGF-1.

Body Pharm AOD-9604 2mg, Product Specifications

Each Body Pharm unit ships as a single 2mg lyophilised powder vial of AOD-9604 (HGH fragment 176–191 analogue, molecular weight ≈1.81 kDa), manufactured by Body Pharm for in vitro research use only and not for human consumption.

Purity is specified as research-grade. A batch-specific Certificate of Analysis is available on request from the supplier. Procurement officers should obtain the CoA for the exact lot prior to assay validation rather than relying on a generic purity figure, lot-to-lot variation can occur even within a single manufacturer. Comparable research-grade AOD-9604 from international suppliers such as Cenexa Labs and XL Peptides is typically certified at ≥99% by HPLC, which sets a reasonable benchmark to verify against the Body Pharm CoA on receipt.

Reconstitution and storage

Reconstitute with bacteriostatic water for laboratory handling, then aliquot to minimise freeze-thaw cycles. Store the unreconstituted vial at −20 °C, desiccated and protected from light, consistent with standard handling for lyophilised peptide biologics. Reconstituted working stock is best held at 2–8 °C and used within windows defined by your stability protocol. Unopened lyophilised vials held at −20 °C generally retain specification for 18–24 months from the manufacture date printed on the label.

Packaging and dispatch

Vials ship in discreet, tamper-evident outer packaging via tracked national courier within South Africa. Researchers building a broader GH-axis panel can cross-reference the AOD-9604 category page and the tesamorelin research peptide listing when finalising the procurement basket.

AOD-9604 vs Related GH-Axis Peptides: 2026 Comparison

AOD-9604 is the only peptide in this comparison that drives lipolysis without elevating IGF-1. That property is why it remains the preferred tool for isolating fat-cell metabolic effects from the broader GH/IGF-1 secretagogue cascade. The table below sets it against the three GH-axis peptides most commonly stocked alongside it in South African research catalogues.

Peptide	Sequence / Origin	Primary Research Application	IGF-1 Effect	Typical Vial Size Available Locally
AOD-9604	HGH fragment 176–191, 16-aa with N-terminal Tyr, ≈1.81 kDa	In vitro lipolysis and adipocyte fat-metabolism assays	None reported in published preclinical work	2mg
Tesamorelin	Synthetic GHRH(1–44) analogue with trans-3-hexenoic acid modification	Visceral adipose tissue reduction models; HIV-associated lipodystrophy research context	Indirect IGF-1 elevation via endogenous GH pulse	2mg
CJC-1295	GHRH(1–29) analogue (with or without DAC)	GH secretagogue studies, sustained GH/IGF-1 elevation models	Direct IGF-1 elevation	2mg
Ipamorelin	Pentapeptide GHRP, ghrelin receptor agonist	Selective GH pulse without significant cortisol/prolactin perturbation	Indirect IGF-1 elevation via GH pulse	2mg

Research notes

I compiled this table in April 2026 by cross-referencing PubMed-indexed primary literature for each compound against current South African research-peptide catalogue listings. The AOD-9604 rows draw on Heffernan et al. (2001) for the lipolytic-without-IGF-1 characterisation and the Biotech Peptides 2024 structural summary for sequence and molecular weight. The GHRH-analogue and GHRP rows reflect mechanism-of-action consensus from secondary review literature rather than new post-2020 trials. No major clinical updates have been published for AOD-9604 since the Metabolic Pharmaceuticals programme.

For procurement officers building a parallel GH-axis study arm, the AOD-9604 category page and the tesamorelin research peptide listing are the appropriate cross-references on this site.

Regulatory Context for South African Researchers

AOD-9604 is not registered as a medicine with SAHPRA as of 2026. No public Government Gazette entry names HGH fragment 176–191 as a scheduled substance directly. The governing legislation is the Medicines and Related Substances Act 101 of 1965, as amended by Act 14 of 2015. Under this Act, any substance intended for therapeutic use in humans must be registered or compounded under prescription oversight.

In practice, South African suppliers handle AOD-9604 in one of two ways: as a growth-hormone-related peptide requiring prescription oversight when compounded for human use, or as an unregistered research chemical sold strictly for in vitro work. Because SAHPRA has not issued an explicit scheduling determination for the peptide, unregistered GH-derived peptides can be treated as Schedule 5 or Schedule 6 substances at the regulator's discretion. I recommend procurement officers verify the current scheduling status with a registered pharmacist or via SAHPRA's published schedules before raising a purchase order, rather than relying on vendor classification alone.

The Body Pharm 2mg vial supplied through this channel is for in vitro and laboratory research only, not for human therapeutic administration. AOD-9604 remains on the WADA 2025 Prohibited List under the peptide hormones and growth factors category. Any athlete exposure, even incidental, is prohibited in sport.

Before procurement, the responsible investigator should secure clearance from their institutional research ethics committee (for example, a university research ethics committee operating under the National Health Research Ethics Council framework) and document the in vitro scope of the work. The AOD-9604 category page and the tesamorelin research peptide listing carry the same compliance framing for parallel study arms.

How to Reconstitute AOD-9604 for In Vitro Research

Reconstitute a 2mg Body Pharm AOD-9604 vial with 1–2 ml of bacteriostatic water to yield a working stock of 2mg/ml or 1mg/ml respectively, for in vitro use only. The protocol below reflects standard lyophilised peptide handling and assumes the vial has been stored at 2–8 °C since receipt from the AOD-9604 category page listing.

1. Remove the vial from refrigeration and allow it to equilibrate to room temperature (approximately 20–25 °C) for 20–30 minutes before breaking the seal. Cold glass invites condensation onto the lyophilised cake.
2. Draw 1 ml (for 2mg/ml) or 2 ml (for 1mg/ml) of bacteriostatic water into a sterile syringe. Insert the needle through the stopper and release the diluent slowly down the inner wall of the vial. Never inject the stream directly onto the powder.
3. Swirl gently in a circular motion for 10–20 seconds. Do not vortex, invert vigorously, or shake, mechanical shear damages the disulfide bridge in the 16-amino-acid sequence.
4. Allow full dissolution at room temperature, typically 2–5 minutes. The solution should be clear and colourless with no visible particulates.
5. Aliquot into single-use volumes (for example 50–100 µl in low-binding polypropylene tubes) to avoid repeated freeze-thaw cycles. Store working aliquots at 2–8 °C and use within 28 days; archive long-term aliquots at −20 °C.

The same handling logic applies to parallel study arms run with the tesamorelin research peptide stock, though tesamorelin's larger 44-residue structure tolerates marginally higher reconstitution volumes.

Buying AOD-9604 in South Africa: What to Look For

Verify these supplier criteria before placing an order:

• A batch-specific Certificate of Analysis with HPLC purity data (this confirms the peptide meets specification)
• Named manufacturer traceability (so you can verify the source)
• Lyophilised vial format (which preserves stability)
• Climate-appropriate packaging (essential in South African summer heat)
• Tracked courier shipping (to confirm delivery)
• Secure ZAR checkout (to avoid currency conversion markup)

Body Pharm is an identifiable manufacturer rather than a white-label brand. The CoA released with each lot can be matched against the vial number on receipt.

Climate and packaging

Gauteng and Western Cape summer ambient temperatures routinely sit between 25 °C and 35 °C. Cold-chain or insulated packaging with desiccant is the minimum acceptable standard for a 16-amino-acid lyophilised peptide in transit. Lyophilised AOD-9604 tolerates short excursions above 8 °C far better than reconstituted solution does. I only accept vials shipped dry with intact stoppers and visible desiccant.

CoA, pricing and dispatch

Request the current lot CoA from JCSG.org before dispatch and confirm purity is stated by HPLC. Research-grade AOD-9604 from comparable vendors is typically reported at ≥99%. Pricing should be quoted in ZAR at checkout, not converted from USD or GBP at the cart stage. Tracked dispatch to Johannesburg, Cape Town and Durban via mainline domestic couriers generally clears in 1–3 business days.

Researchers ready to procure can add Body Pharm AOD-9604 2mg to a research order via the AOD-9604 category page, or compare it against the tesamorelin research peptide listing if a parallel GHRH-axis arm is planned.

Frequently Asked Questions